Recursion Pharmaceuticals Reports on Shareholder Vote Outcomes
Ticker: RXRX · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1601830
| Field | Detail |
|---|---|
| Company | Recursion Pharmaceuticals, Inc. (RXRX) |
| Form Type | 8-K |
| Filed Date | Jun 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: RXRX
TL;DR
Recursion Pharma shareholders voted on stuff June 3rd, filing shows results.
AI Summary
Recursion Pharmaceuticals, Inc. filed an 8-K on June 7, 2024, to report on matters submitted to a vote of its security holders on June 3, 2024. The filing details the outcomes of this vote, which is a standard procedural update for the company.
Why It Matters
This filing provides transparency on corporate governance decisions made by Recursion Pharmaceuticals' shareholders, which can influence the company's strategic direction and management.
Risk Assessment
Risk Level: low — This is a routine filing reporting on a shareholder vote, with no immediate financial or operational risks indicated.
Key Players & Entities
- RECURSION PHARMACEUTICALS, INC. (company) — Registrant
- June 3, 2024 (date) — Date of earliest event reported
- June 7, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 41 S Rio Grande Street, Salt Lake City, UT 84101 (address) — Principal executive offices
FAQ
What was the specific purpose of the shareholder vote reported in this 8-K?
The 8-K filing indicates that the purpose was to report on 'Submission of Matters to a Vote of Security Holders' that occurred on June 3, 2024.
When was this Form 8-K filed with the SEC?
This Form 8-K was filed as of June 7, 2024.
What is Recursion Pharmaceuticals, Inc.'s state of incorporation?
Recursion Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for Recursion Pharmaceuticals, Inc.?
The principal executive offices are located at 41 S Rio Grande Street, Salt Lake City, UT 84101.
Does this filing report on any new financial results or material agreements?
No, this filing is specifically for reporting on matters submitted to a vote of security holders and does not appear to detail new financial results or material agreements.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-06-07 09:00:35
Key Financial Figures
- $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar
Filing Documents
- rxrx-20240603.htm (8-K) — 26KB
- 0001601830-24-000076.txt ( ) — 145KB
- rxrx-20240603.xsd (EX-101.SCH) — 2KB
- rxrx-20240603_lab.xml (EX-101.LAB) — 21KB
- rxrx-20240603_pre.xml (EX-101.PRE) — 12KB
- rxrx-20240603_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. Recursion Pharmaceuticals, Inc. (the "Company") held its 2024 annual meeting of stockholders ("Annual Meeting") on June 3, 2024. At the Annual Meeting, the Company's stockholders voted on the following proposals, each of which is described in more detail in the Company's definitive Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 23, 2024 (the "Proxy Statement"): Proposal 1: The stockholders elected as Class III directors the two individuals listed below to serve until the Company's 2027 annual meeting of stockholders, or until their respective successors are duly elected and qualified. The voting results were as follows: Nominee For Withheld Broker Non-Votes Blake Borgeson, Ph.D. 165,914,956 26,093,759 0 Dean Y. Li, M.D., Ph.D. 166,211,058 25,797,657 0 Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast: For Against Abstain Broker Non-Votes 188,317,831 2,887,180 803,704 0
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on June 7, 2024. RECURSION PHARMACEUTICALS, INC. By: /s/ Nathan Hatfield Nathan Hatfield Chief Legal Officer